8-K: Catheter Precision Secures $500,000 Loan and Formalizes Royalty Agreement

Catheter Precision has entered into a royalty agreement with a co-inventor of their LockeT device and secured a $500,000 short-term loan from its Executive Chair and CEO.

Summary

• Catheter Precision has formalized a royalty agreement with Auston Locke, a co-inventor of the LockeT device, which extends the terms of their previous agreement.
• The company will pay Locke a 5% royalty on net sales of the LockeT device until $1 million in cumulative royalties is reached.
• After $1 million, and if a patent is obtained, the royalty rate will reduce to 2% until a total of $10 million in royalties is paid.
• No further royalty payments will be due after December 31, 2033, or after the expiration of the relevant patents.
• Additionally, Catheter Precision received a $500,000 short-term loan from its Executive Chair and CEO, David A. Jenkins.
• The loan has an 8% annual interest rate and matures on August 30, 2024.
• The loan agreement includes standard default clauses, such as failure to pay or a material breach of warranties.

Sentiment

Score: 6

Explanation: The news is mixed, with a positive formalization of the royalty agreement but also the burden of a short-term loan. The sentiment is neutral to slightly positive.

Positives

• The royalty agreement with Auston Locke provides clarity and a defined structure for future payments related to the LockeT device.
• Securing a $500,000 loan provides the company with immediate capital to support operations.

Negatives

• The company is taking on debt with an 8% interest rate, which could impact profitability.
• The royalty payments, while capped, will reduce revenue from the LockeT device.

Risks

• The company's ability to repay the $500,000 loan by August 30, 2024, is a short-term financial risk.
• Failure to obtain a patent for the LockeT device would prevent the royalty rate from reducing to 2% after the first $1 million in payments.
• The company is reliant on the success of the LockeT device to generate revenue and meet its royalty obligations.

Future Outlook

The company will need to generate sufficient sales of the LockeT device to meet its royalty obligations and repay the short-term loan by August 30, 2024. The company is also dependent on obtaining a patent for the LockeT device to reduce the royalty rate.

Management Comments

• The company has formalized the terms of the agreement with Mr. Locke with respect to the company's LockeT device.
• The company has entered into a short term loan agreement with its Executive Chair and CEO.

Industry Context

The medical device industry often involves complex intellectual property agreements and requires significant capital investment. This announcement reflects the typical financial and legal activities of a company in this sector.

Comparison to Industry Standards

• Royalty rates in the medical device industry can vary widely, but 5% is a reasonable initial rate for a co-inventor, with a reduction to 2% upon patent approval being a common practice.
• Short-term loans from executives are not uncommon for smaller medical device companies, especially during development and commercialization phases.
• Companies like Medtronic and Boston Scientific often have complex royalty and licensing agreements, but these are typically with larger institutions or other companies, not individual inventors.

Related Party Transactions

• The $500,000 loan from David A. Jenkins, the Executive Chair and CEO, is a related party transaction.
• David A. Jenkins is also a co-inventor of certain products and has royalty rights on sales of the LockeT device.

Stakeholder Impact

• Shareholders may view the loan as a short-term risk but also a necessary step for the company's operations.
• Employees may be impacted by the company's ability to meet its financial obligations.
• Customers may be impacted by the company's ability to continue to develop and sell the LockeT device.

Next Steps

• The company needs to focus on sales of the LockeT device to meet royalty obligations.
• The company needs to repay the $500,000 loan by August 30, 2024.
• The company needs to secure a patent for the LockeT device to reduce the royalty rate.

Key Dates

Keywords

royalty agreement, short-term loan, LockeT device, patent, net sales, promissory note, related party transaction, medical device